Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 10/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.33 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL947140 | 0.89 | PDE10A (0.30) | — | |
| SCHEMBL19497557 | 0.72 | — | — | |
| SCHEMBL19029249 | 0.70 | PLK1 (0.36) | HSD17B10KDM4ECYP11B2NR3C1PLK1 | |
| SCHEMBL18366019 | 0.70 | ALOX5 (0.36) | HSD17B10CYP11B2NR3C1 | |
| SCHEMBL18366021 | 0.70 | BRD4 (0.38) | HSD17B10CYP11B2 | |
| SCHEMBL21191004 | 0.69 | PARP1 (0.49) | — | |
| SCHEMBL22854641 | 0.67 | HSD17B10 (0.47) | HSD17B10KDM4E | |
| SCHEMBL31332827 | 0.65 | CYP11B2 (0.33) | CYP11B2 | |
| SCHEMBL13255590 | 0.65 | CHRM2 (0.36) | PLK1CSNK2A1PLK3 | |
| SCHEMBL19028806 | 0.65 | PDPK1 (0.47) | HSD17B10PLK1CSNK2A1PLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-05-22 | — | — | US | claimed |
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-05-22 | — | — | US | disclosed |
| WO-2008024978-A2 | TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
| WO-2008024978-A2 | TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119457-A1 | Benzene, Pyridine, and Pyridazine Derivatives | MKI67, CCNB1, RB1 | HSD17B10 3567/4885KDM4E 1597/4885CYP11B2 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.